Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.31 |
| ▸ | CCND1 | P24385 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299330 | 0.94 | GAA (0.34) | GAAHPGDSMN1; SMN2 | |
| SCHEMBL30299337 | 0.89 | FPR1 (0.37) | CDK4CDK2JAK2 | |
| SCHEMBL30299352 | 0.86 | HTR1D (0.35) | GAAHPGDSMN1; SMN2 | |
| SCHEMBL30090537 | 0.85 | TNIK (0.36) | CDK4CDK2GAAJAK2 | |
| SCHEMBL30299336 | 0.82 | JAK2 (0.35) | CDK4CDK2GAAHPGDSMN1; SMN2 | |
| SCHEMBL30299403 | 0.80 | MAP4K4 (0.34) | CDK4CCND1CDK2JAK2 | |
| SCHEMBL30299377 | 0.80 | PDE3B (0.34) | GAAHPGDSMN1; SMN2 | |
| SCHEMBL30299381 | 0.80 | IP6K1 (0.32) | — | |
| SCHEMBL30299387 | 0.79 | OPRM1 (0.31) | — | |
| SCHEMBL30299371 | 0.77 | ALDH1A1 (0.43) | GAAWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110551105-B | Substituted triazoles useful as AXL inhibitors | 里格尔制药公司 | 2022-10-18 | — | — | CN | claimed |
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-110551105-B | Substituted triazoles useful as AXL inhibitors | 里格尔制药公司 | 2022-10-18 | — | — | CN | disclosed |